Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan’s Generic Advair Delay Gives Leverage To Rivals

Executive Summary

Mylan received a “complete response” letter from FDA on its application for a generic version of GSK’s blockbuster Advair, offering scarce details on the reason why or possible length of the delay.

Advertisement

Related Content

Mylan Sees Generic Advair Marathon Nearing FDA Finish Line
Mylan Sees Generic Advair Marathon Nearing FDA Finish Line
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
Mylan Preparing Response To Generic Advair CRL, And It Needs A Win
Mylan Preparing Response To Generic Advair CRL, And It Needs A Win
Advair Generic Approval Uncertain Despite US FDA Denial Of Sandoz Petition
Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel